Who is retatrutide suitable for?
Retatrutide will likely be indicated for adult patients with an initial BMI (Body Mass Index) of:
≥ 30 BMI (obesity), or
≥ 27 BMI to < 30 BMI (overweight) who have at least one weight-related comorbidity, such as diabetes, high blood pressure, high cholesterol, osteoarthritis, or sleep apnea.
The final indication will follow once the medicine is approved.
Retatrutide prescription
Retatrutide is only available by prescription from a doctor if the patient meets the indications described above. However, the research phase still needs to be completed, and it is not yet clear whether and when it will enter the Dutch market.
How retatrutide works
Retatrutide is a medicine that affects 3 hormone receptors: the GLP-1 hormone, Glucagon, and GIP hormone. These help regulate blood glucose levels, contribute to insulin secretion, aid in hunger and satiety, stimulate fat burning, and thereby the energy balance.
Is retatrutide safe?
Retatrutide has not yet been approved by the FDA and the Ministry of Health. The medicine is still in the research phase and therefore cannot yet receive approval.
The difference between retatrutide and tirzepatide
The action of tirzepatide is dual, and the action of retatrutide is triple.
Retatrutide reimbursement by health insurance
The medicine retatrutide has not yet been approved by the FDA and the Ministry of Health. Therefore, it cannot yet be said whether it will be reimbursed in the future.
Retatrutide dosage
The dosages of retatrutide during studies are 1 mg, 2 mg, 4 mg, 8 mg, and 12 mg. Which dosages will be available in the future depends on further research and approval from the FDA and the Ministry of Health.
Where do you inject retatrutide?
Retatrutide is administered via a subcutaneous injection. Do not inject it into a vein or muscle. The best places to inject are:
- in the thigh
- in the lower abdomen
- in the upper arm
